Kerry Lynn Reynolds, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neoplasms | 44 | 2024 | 22032 | 1.700 |
Why?
|
Immunotherapy | 19 | 2023 | 4641 | 1.450 |
Why?
|
Acute Kidney Injury | 13 | 2024 | 1926 | 1.280 |
Why?
|
Melanoma | 18 | 2024 | 5691 | 1.210 |
Why?
|
Drug Eruptions | 10 | 2024 | 335 | 1.200 |
Why?
|
Myocarditis | 12 | 2022 | 766 | 1.170 |
Why?
|
Pemphigoid, Bullous | 4 | 2022 | 114 | 0.690 |
Why?
|
Medical Oncology | 5 | 2022 | 2312 | 0.660 |
Why?
|
Stevens-Johnson Syndrome | 4 | 2023 | 244 | 0.630 |
Why?
|
Colitis | 6 | 2024 | 1229 | 0.630 |
Why?
|
Neurotoxicity Syndromes | 2 | 2020 | 300 | 0.610 |
Why?
|
Aspergillosis | 1 | 2020 | 243 | 0.600 |
Why?
|
Exanthema | 4 | 2024 | 504 | 0.600 |
Why?
|
Prednisone | 2 | 2021 | 1565 | 0.600 |
Why?
|
Lung Neoplasms | 13 | 2024 | 13245 | 0.580 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 6 | 2024 | 5246 | 0.570 |
Why?
|
Myositis | 2 | 2020 | 269 | 0.540 |
Why?
|
Hepatitis | 1 | 2018 | 229 | 0.530 |
Why?
|
Practice Guidelines as Topic | 4 | 2021 | 7378 | 0.490 |
Why?
|
Pneumonia | 3 | 2022 | 2129 | 0.450 |
Why?
|
Carcinoma, Renal Cell | 3 | 2023 | 3217 | 0.440 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 9 | 2022 | 11709 | 0.410 |
Why?
|
Humans | 128 | 2024 | 758406 | 0.400 |
Why?
|
Cross Infection | 1 | 2021 | 1432 | 0.390 |
Why?
|
Adrenal Cortex Hormones | 7 | 2022 | 1870 | 0.390 |
Why?
|
Nephritis, Interstitial | 3 | 2023 | 154 | 0.390 |
Why?
|
Hypokalemia | 2 | 2023 | 152 | 0.380 |
Why?
|
Thyroiditis | 2 | 2021 | 86 | 0.370 |
Why?
|
Retrospective Studies | 51 | 2024 | 80168 | 0.370 |
Why?
|
Enterocolitis | 2 | 2023 | 106 | 0.360 |
Why?
|
Nervous System Diseases | 1 | 2021 | 1647 | 0.360 |
Why?
|
Skin Diseases | 4 | 2024 | 1088 | 0.360 |
Why?
|
Kidney Neoplasms | 3 | 2023 | 4312 | 0.350 |
Why?
|
Aromatase Inhibitors | 1 | 2013 | 511 | 0.330 |
Why?
|
Middle Aged | 59 | 2024 | 219568 | 0.320 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2016 | 1530 | 0.320 |
Why?
|
Aged | 55 | 2024 | 168218 | 0.320 |
Why?
|
Tamoxifen | 1 | 2013 | 963 | 0.320 |
Why?
|
Skin Neoplasms | 6 | 2024 | 5797 | 0.310 |
Why?
|
Disease Management | 4 | 2019 | 2500 | 0.310 |
Why?
|
Antineoplastic Agents | 5 | 2023 | 13591 | 0.290 |
Why?
|
Stomach Neoplasms | 1 | 2017 | 1422 | 0.290 |
Why?
|
Esophageal Neoplasms | 1 | 2017 | 1648 | 0.280 |
Why?
|
Male | 61 | 2024 | 358747 | 0.270 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3076 | 0.250 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3196 | 0.250 |
Why?
|
Inpatients | 3 | 2021 | 2551 | 0.250 |
Why?
|
Cohort Studies | 17 | 2024 | 41256 | 0.240 |
Why?
|
Breast Neoplasms | 6 | 2020 | 21017 | 0.230 |
Why?
|
Head and Neck Neoplasms | 2 | 2020 | 2882 | 0.230 |
Why?
|
Female | 57 | 2024 | 390323 | 0.220 |
Why?
|
Skin | 8 | 2023 | 4464 | 0.220 |
Why?
|
Paranoid Disorders | 1 | 2023 | 61 | 0.210 |
Why?
|
Immunosuppressive Agents | 4 | 2024 | 4158 | 0.210 |
Why?
|
Erythema Multiforme | 1 | 2022 | 31 | 0.200 |
Why?
|
Aged, 80 and over | 22 | 2024 | 58683 | 0.200 |
Why?
|
Lichenoid Eruptions | 1 | 2021 | 13 | 0.200 |
Why?
|
Cardiac Imaging Techniques | 2 | 2021 | 267 | 0.200 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2017 | 4023 | 0.200 |
Why?
|
Incidence | 8 | 2024 | 21272 | 0.190 |
Why?
|
Vitiligo | 1 | 2022 | 97 | 0.190 |
Why?
|
Glomerular Filtration Rate | 4 | 2023 | 2154 | 0.190 |
Why?
|
Hyperkalemia | 1 | 2023 | 231 | 0.190 |
Why?
|
Immunotherapy, Adoptive | 2 | 2021 | 1454 | 0.180 |
Why?
|
Surge Capacity | 1 | 2020 | 48 | 0.180 |
Why?
|
Administration, Cutaneous | 4 | 2023 | 712 | 0.180 |
Why?
|
Caregivers | 2 | 2024 | 2225 | 0.180 |
Why?
|
Nephritis | 1 | 2021 | 147 | 0.170 |
Why?
|
Censuses | 1 | 2021 | 201 | 0.170 |
Why?
|
Pneumonia, Bacterial | 1 | 2022 | 318 | 0.170 |
Why?
|
Eczema | 1 | 2022 | 245 | 0.170 |
Why?
|
Patient Care Team | 2 | 2021 | 2504 | 0.170 |
Why?
|
Takotsubo Cardiomyopathy | 1 | 2021 | 123 | 0.170 |
Why?
|
Genes, cdc | 1 | 2019 | 115 | 0.160 |
Why?
|
Skin Diseases, Vesiculobullous | 1 | 2020 | 85 | 0.160 |
Why?
|
Pericardial Effusion | 1 | 2021 | 247 | 0.160 |
Why?
|
Hyponatremia | 1 | 2021 | 279 | 0.160 |
Why?
|
Water-Electrolyte Imbalance | 1 | 2020 | 109 | 0.160 |
Why?
|
Polymyalgia Rheumatica | 1 | 2018 | 53 | 0.160 |
Why?
|
Lymphocyte Count | 1 | 2020 | 778 | 0.160 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2024 | 2004 | 0.150 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2023 | 2239 | 0.150 |
Why?
|
Ablation Techniques | 1 | 2021 | 248 | 0.150 |
Why?
|
Cisplatin | 1 | 2024 | 1645 | 0.150 |
Why?
|
Community-Institutional Relations | 1 | 2019 | 208 | 0.150 |
Why?
|
Receptor, erbB-2 | 2 | 2018 | 2553 | 0.140 |
Why?
|
Anemia, Hemolytic, Autoimmune | 1 | 2019 | 146 | 0.140 |
Why?
|
Budgets | 1 | 2019 | 229 | 0.140 |
Why?
|
Renin-Angiotensin System | 1 | 2022 | 733 | 0.140 |
Why?
|
Patient Simulation | 1 | 2019 | 297 | 0.140 |
Why?
|
Hospitalization | 5 | 2024 | 10652 | 0.140 |
Why?
|
Creatinine | 4 | 2024 | 1892 | 0.140 |
Why?
|
Receptor, erbB-3 | 1 | 2017 | 143 | 0.140 |
Why?
|
Colon | 2 | 2024 | 1787 | 0.130 |
Why?
|
Cough | 1 | 2020 | 594 | 0.130 |
Why?
|
Positron-Emission Tomography | 2 | 2024 | 6457 | 0.130 |
Why?
|
Arthritis, Psoriatic | 1 | 2018 | 219 | 0.130 |
Why?
|
Bacteremia | 1 | 2022 | 980 | 0.130 |
Why?
|
Prognosis | 7 | 2021 | 29557 | 0.130 |
Why?
|
Heart Conduction System | 1 | 2021 | 1011 | 0.130 |
Why?
|
Consensus | 2 | 2024 | 3099 | 0.130 |
Why?
|
Fatal Outcome | 1 | 2020 | 1829 | 0.120 |
Why?
|
Piperidines | 1 | 2023 | 1639 | 0.120 |
Why?
|
Adult | 22 | 2024 | 219935 | 0.120 |
Why?
|
Maximum Tolerated Dose | 1 | 2017 | 876 | 0.120 |
Why?
|
Dermatology | 2 | 2022 | 914 | 0.120 |
Why?
|
Methotrexate | 1 | 2021 | 1719 | 0.120 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2023 | 2057 | 0.120 |
Why?
|
Combined Modality Therapy | 3 | 2022 | 8530 | 0.110 |
Why?
|
Community Health Services | 1 | 2019 | 656 | 0.110 |
Why?
|
Celiac Disease | 1 | 2022 | 822 | 0.110 |
Why?
|
Qualitative Research | 1 | 2024 | 2976 | 0.110 |
Why?
|
Organ Transplantation | 1 | 2024 | 1150 | 0.110 |
Why?
|
Drug Costs | 2 | 2019 | 1178 | 0.110 |
Why?
|
Neoadjuvant Therapy | 3 | 2020 | 2821 | 0.110 |
Why?
|
Physician's Role | 1 | 2020 | 917 | 0.110 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2019 | 708 | 0.110 |
Why?
|
Action Potentials | 1 | 2021 | 1816 | 0.110 |
Why?
|
Patient Admission | 1 | 2021 | 1372 | 0.110 |
Why?
|
Radiography, Thoracic | 1 | 2020 | 1296 | 0.110 |
Why?
|
Drug Hypersensitivity | 1 | 2022 | 915 | 0.110 |
Why?
|
Hospice Care | 1 | 2020 | 677 | 0.110 |
Why?
|
Kidney | 3 | 2023 | 7016 | 0.110 |
Why?
|
Brachytherapy | 1 | 2021 | 1236 | 0.110 |
Why?
|
Bayes Theorem | 2 | 2020 | 2322 | 0.110 |
Why?
|
Intestinal Mucosa | 1 | 2024 | 3020 | 0.110 |
Why?
|
Single-Cell Analysis | 1 | 2024 | 2379 | 0.110 |
Why?
|
Hemoglobins | 1 | 2019 | 1519 | 0.110 |
Why?
|
Registries | 5 | 2021 | 8175 | 0.110 |
Why?
|
Patient Education as Topic | 2 | 2020 | 2307 | 0.100 |
Why?
|
Risk Factors | 14 | 2024 | 73809 | 0.100 |
Why?
|
Biopsy | 2 | 2021 | 6768 | 0.100 |
Why?
|
Pandemics | 3 | 2021 | 8611 | 0.100 |
Why?
|
Dyspnea | 1 | 2020 | 1344 | 0.100 |
Why?
|
Antibodies, Monoclonal | 4 | 2023 | 9160 | 0.100 |
Why?
|
Molecular Targeted Therapy | 2 | 2020 | 2796 | 0.100 |
Why?
|
Pyrimidines | 1 | 2023 | 3006 | 0.100 |
Why?
|
Influenza Vaccines | 1 | 2019 | 759 | 0.100 |
Why?
|
Terminal Care | 2 | 2020 | 1750 | 0.090 |
Why?
|
Massachusetts | 2 | 2021 | 8823 | 0.090 |
Why?
|
Embolization, Therapeutic | 1 | 2021 | 1407 | 0.090 |
Why?
|
Hematologic Neoplasms | 1 | 2022 | 1890 | 0.090 |
Why?
|
Renal Dialysis | 1 | 2020 | 1786 | 0.090 |
Why?
|
Research | 1 | 2019 | 1976 | 0.090 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2019 | 3992 | 0.090 |
Why?
|
Autoimmune Diseases | 1 | 2022 | 2244 | 0.090 |
Why?
|
Referral and Consultation | 2 | 2021 | 3586 | 0.090 |
Why?
|
Immunohistochemistry | 1 | 2023 | 11070 | 0.090 |
Why?
|
Treatment Outcome | 9 | 2023 | 64378 | 0.090 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2020 | 1402 | 0.080 |
Why?
|
Drug Prescriptions | 1 | 2019 | 1668 | 0.080 |
Why?
|
Anti-Inflammatory Agents | 1 | 2019 | 1793 | 0.080 |
Why?
|
Heart Rate | 1 | 2021 | 4166 | 0.080 |
Why?
|
Plaque, Atherosclerotic | 1 | 2020 | 1505 | 0.080 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2020 | 10748 | 0.080 |
Why?
|
Heart Diseases | 1 | 2022 | 2782 | 0.080 |
Why?
|
Tomography, X-Ray Computed | 3 | 2021 | 20500 | 0.080 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2021 | 2276 | 0.080 |
Why?
|
Receptors, Estrogen | 1 | 2016 | 2210 | 0.080 |
Why?
|
Neutrophils | 1 | 2020 | 3765 | 0.070 |
Why?
|
Diagnosis, Differential | 2 | 2020 | 12951 | 0.070 |
Why?
|
Kidney Failure, Chronic | 1 | 2020 | 2457 | 0.070 |
Why?
|
Influenza, Human | 1 | 2019 | 1516 | 0.070 |
Why?
|
Electrocardiography | 1 | 2021 | 6363 | 0.070 |
Why?
|
Echocardiography | 1 | 2020 | 4962 | 0.070 |
Why?
|
Risk Assessment | 7 | 2024 | 23884 | 0.070 |
Why?
|
Cost-Benefit Analysis | 4 | 2020 | 5484 | 0.070 |
Why?
|
Troponin T | 2 | 2022 | 761 | 0.060 |
Why?
|
Models, Economic | 2 | 2019 | 715 | 0.060 |
Why?
|
Predictive Value of Tests | 4 | 2022 | 15225 | 0.060 |
Why?
|
Liver | 1 | 2020 | 7502 | 0.060 |
Why?
|
Time Factors | 6 | 2021 | 39872 | 0.060 |
Why?
|
Atherosclerosis | 1 | 2020 | 3401 | 0.060 |
Why?
|
Pain | 1 | 2019 | 5065 | 0.060 |
Why?
|
Carcinoma in Situ | 1 | 2010 | 796 | 0.060 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2019 | 5249 | 0.060 |
Why?
|
Radioimmunotherapy | 1 | 2024 | 91 | 0.060 |
Why?
|
ROC Curve | 2 | 2022 | 3563 | 0.060 |
Why?
|
Ventricular Function, Left | 3 | 2022 | 3858 | 0.050 |
Why?
|
Clinical Competence | 1 | 2019 | 4775 | 0.050 |
Why?
|
Genome-Wide Association Study | 1 | 2022 | 12604 | 0.050 |
Why?
|
Arthritis, Rheumatoid | 1 | 2018 | 3755 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 2 | 2021 | 36284 | 0.050 |
Why?
|
Baclofen | 1 | 2023 | 120 | 0.050 |
Why?
|
Stroke Volume | 3 | 2022 | 5460 | 0.050 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2010 | 1096 | 0.050 |
Why?
|
Lactate Dehydrogenases | 1 | 2022 | 27 | 0.050 |
Why?
|
Interleukin-7 | 1 | 2022 | 142 | 0.050 |
Why?
|
Digoxin | 1 | 2023 | 246 | 0.050 |
Why?
|
Quality-Adjusted Life Years | 2 | 2019 | 1722 | 0.050 |
Why?
|
Cystatin C | 1 | 2023 | 270 | 0.050 |
Why?
|
Hypertension | 1 | 2022 | 8499 | 0.050 |
Why?
|
Telemedicine | 1 | 2019 | 3018 | 0.050 |
Why?
|
Drug Administration Schedule | 2 | 2020 | 4839 | 0.050 |
Why?
|
Phenotype | 1 | 2019 | 16534 | 0.050 |
Why?
|
Calcitonin | 1 | 2022 | 330 | 0.050 |
Why?
|
Lung | 1 | 2020 | 9985 | 0.050 |
Why?
|
Physicians | 1 | 2019 | 4580 | 0.050 |
Why?
|
Electrolytes | 1 | 2021 | 274 | 0.050 |
Why?
|
Oximes | 1 | 2022 | 303 | 0.040 |
Why?
|
Neoplasm Staging | 3 | 2019 | 11152 | 0.040 |
Why?
|
Vancomycin | 1 | 2023 | 503 | 0.040 |
Why?
|
Karnofsky Performance Status | 1 | 2020 | 165 | 0.040 |
Why?
|
Disease-Free Survival | 2 | 2020 | 6821 | 0.040 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2020 | 3527 | 0.040 |
Why?
|
Appendectomy | 1 | 2023 | 431 | 0.040 |
Why?
|
Myocardial Infarction | 1 | 2020 | 11424 | 0.040 |
Why?
|
Pyrimidinones | 1 | 2022 | 383 | 0.040 |
Why?
|
Adrenal Gland Diseases | 1 | 2020 | 141 | 0.040 |
Why?
|
Glucocorticoids | 2 | 2019 | 2144 | 0.040 |
Why?
|
Cardiovascular Diseases | 2 | 2022 | 15399 | 0.040 |
Why?
|
Tomography | 1 | 2021 | 411 | 0.040 |
Why?
|
Azithromycin | 1 | 2020 | 200 | 0.040 |
Why?
|
Urogenital Neoplasms | 1 | 2020 | 135 | 0.040 |
Why?
|
Water-Electrolyte Balance | 1 | 2020 | 325 | 0.040 |
Why?
|
Germ Cells | 1 | 2022 | 635 | 0.040 |
Why?
|
Colorectal Neoplasms | 1 | 2018 | 6852 | 0.040 |
Why?
|
Brain Neoplasms | 1 | 2020 | 8981 | 0.040 |
Why?
|
United States | 6 | 2022 | 72136 | 0.040 |
Why?
|
Polyneuropathies | 1 | 2019 | 137 | 0.040 |
Why?
|
Boston | 2 | 2021 | 9304 | 0.040 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2020 | 9273 | 0.040 |
Why?
|
Hospices | 1 | 2020 | 245 | 0.040 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2023 | 1086 | 0.040 |
Why?
|
Organoplatinum Compounds | 1 | 2018 | 405 | 0.040 |
Why?
|
Interviews as Topic | 1 | 2024 | 2676 | 0.040 |
Why?
|
Myocardial Revascularization | 1 | 2020 | 792 | 0.030 |
Why?
|
Leucovorin | 1 | 2018 | 641 | 0.030 |
Why?
|
Pyridones | 1 | 2022 | 784 | 0.030 |
Why?
|
Methylprednisolone | 1 | 2018 | 384 | 0.030 |
Why?
|
Carboplatin | 1 | 2019 | 788 | 0.030 |
Why?
|
Sodium | 1 | 2021 | 1588 | 0.030 |
Why?
|
Hydroxychloroquine | 1 | 2020 | 426 | 0.030 |
Why?
|
Carcinoma, Merkel Cell | 1 | 2020 | 321 | 0.030 |
Why?
|
Interleukin-2 | 1 | 2023 | 1888 | 0.030 |
Why?
|
Imidazoles | 1 | 2022 | 1179 | 0.030 |
Why?
|
DNA Mismatch Repair | 1 | 2018 | 428 | 0.030 |
Why?
|
Markov Chains | 1 | 2019 | 965 | 0.030 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2022 | 1016 | 0.030 |
Why?
|
Hypothyroidism | 1 | 2020 | 665 | 0.030 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 1503 | 0.030 |
Why?
|
Gadolinium | 1 | 2020 | 959 | 0.030 |
Why?
|
Databases, Factual | 2 | 2021 | 7980 | 0.030 |
Why?
|
Ligands | 1 | 2022 | 3258 | 0.030 |
Why?
|
Microsatellite Instability | 1 | 2018 | 715 | 0.030 |
Why?
|
Patient Care | 1 | 2020 | 622 | 0.030 |
Why?
|
Proton Pump Inhibitors | 1 | 2019 | 529 | 0.030 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2023 | 2532 | 0.030 |
Why?
|
Fluorouracil | 1 | 2018 | 1631 | 0.030 |
Why?
|
Magnetic Resonance Imaging, Cine | 1 | 2020 | 1044 | 0.030 |
Why?
|
Brain | 1 | 2020 | 26947 | 0.030 |
Why?
|
Disease Progression | 2 | 2020 | 13468 | 0.030 |
Why?
|
Patient Preference | 1 | 2020 | 921 | 0.030 |
Why?
|
Antihypertensive Agents | 1 | 2022 | 2016 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2024 | 3664 | 0.020 |
Why?
|
Prospective Studies | 3 | 2022 | 54137 | 0.020 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2022 | 2053 | 0.020 |
Why?
|
Paclitaxel | 1 | 2019 | 1728 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2020 | 22029 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2022 | 3812 | 0.020 |
Why?
|
Recovery of Function | 1 | 2021 | 2970 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2024 | 4549 | 0.020 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2024 | 3071 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2020 | 2751 | 0.020 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2020 | 3759 | 0.020 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2024 | 3432 | 0.020 |
Why?
|
Cause of Death | 1 | 2020 | 3675 | 0.020 |
Why?
|
Immunologic Factors | 1 | 2018 | 1585 | 0.020 |
Why?
|
Acute Disease | 1 | 2019 | 7225 | 0.020 |
Why?
|
Decision Support Techniques | 1 | 2019 | 1996 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2019 | 4901 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2024 | 9404 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2021 | 3732 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2020 | 3056 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2023 | 5629 | 0.020 |
Why?
|
Survival Analysis | 1 | 2020 | 10112 | 0.020 |
Why?
|
Contrast Media | 1 | 2020 | 5298 | 0.020 |
Why?
|
Vaccination | 1 | 2019 | 3355 | 0.020 |
Why?
|
Diabetes Mellitus | 1 | 2024 | 5816 | 0.020 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 3227 | 0.020 |
Why?
|
Comorbidity | 1 | 2020 | 10495 | 0.020 |
Why?
|
Cognition | 1 | 2022 | 6953 | 0.020 |
Why?
|
Logistic Models | 1 | 2020 | 13276 | 0.020 |
Why?
|
Survival Rate | 1 | 2019 | 12721 | 0.020 |
Why?
|
Perception | 1 | 2010 | 1197 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2021 | 7403 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2019 | 15785 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2016 | 10146 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2020 | 25956 | 0.010 |
Why?
|
Mutation | 1 | 2022 | 29915 | 0.010 |
Why?
|
Quality of Life | 1 | 2019 | 13285 | 0.010 |
Why?
|
Adolescent | 1 | 2019 | 87892 | 0.010 |
Why?
|